ParkinsonCanadaV1, Ncbi, Merge, bibRecord, 000848

Clinical practice regarding dopamine-agonist use and driving in Parkinson's disease.

Identifieur interne : 000848 ( Ncbi/Merge ); précédent : 000847; suivant : 000849

Clinical practice regarding dopamine-agonist use and driving in Parkinson's disease.

Auteurs : R M A. De Bie [Canada] ; J. Miyasaki ; A E Lang ; S H Fox

Source :

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques [ 0317-1671 ] ; 2007.

RBID : pubmed:18062452

Descripteurs français

Wicri :
- geographic : Canada.

English descriptors

KwdEn :
- Automobile Driving, Canada, Disorders of Excessive Somnolence (chemically induced), Dopamine Agonists (adverse effects), Dopamine Agonists (therapeutic use), Guideline Adherence (statistics & numerical data), Guidelines as Topic, Humans, Parkinson Disease (drug therapy), Practice Patterns, Physicians' (statistics & numerical data).
MESH :
- chemical , adverse effects : Dopamine Agonists.
- chemical , therapeutic use : Dopamine Agonists.
- geographic : Canada.
- chemically induced : Disorders of Excessive Somnolence.
- drug therapy : Parkinson Disease.
- statistics & numerical data : Guideline Adherence, Practice Patterns, Physicians'.
- Automobile Driving, Guidelines as Topic, Humans.

Abstract

Current Health Canada instructions for use of the dopamine agonists (DA), pramipexole and ropinirole, state that Parkinson's disease (PD) patients should be told not to drive. The objective was to assess neurologists' actual clinical practice concerning driving advice they give to PD patients starting a DA.

PubMed: 18062452

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 001036
to stream PubMed, to step Curation: 001036
to stream PubMed, to step Checkpoint: 001036

Links to Exploration step

pubmed:18062452

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical practice regarding dopamine-agonist use and driving in Parkinson's disease.</title>
<author><name sortKey="De Bie, R M A" sort="De Bie, R M A" uniqKey="De Bie R" first="R M A" last="De Bie">R M A. De Bie</name>
<affiliation wicri:level="4"><nlm:affiliation>Movement Disorders Centre, Division of Neurology University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorders Centre, Division of Neurology University of Toronto, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Miyasaki, J" sort="Miyasaki, J" uniqKey="Miyasaki J" first="J" last="Miyasaki">J. Miyasaki</name>
</author>
<author><name sortKey="Lang, A E" sort="Lang, A E" uniqKey="Lang A" first="A E" last="Lang">A E Lang</name>
</author>
<author><name sortKey="Fox, S H" sort="Fox, S H" uniqKey="Fox S" first="S H" last="Fox">S H Fox</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2007">2007</date>
<idno type="RBID">pubmed:18062452</idno>
<idno type="pmid">18062452</idno>
<idno type="wicri:Area/PubMed/Corpus">001036</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001036</idno>
<idno type="wicri:Area/PubMed/Curation">001036</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001036</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001036</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001036</idno>
<idno type="wicri:Area/Ncbi/Merge">000848</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Clinical practice regarding dopamine-agonist use and driving in Parkinson's disease.</title>
<author><name sortKey="De Bie, R M A" sort="De Bie, R M A" uniqKey="De Bie R" first="R M A" last="De Bie">R M A. De Bie</name>
<affiliation wicri:level="4"><nlm:affiliation>Movement Disorders Centre, Division of Neurology University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorders Centre, Division of Neurology University of Toronto, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Miyasaki, J" sort="Miyasaki, J" uniqKey="Miyasaki J" first="J" last="Miyasaki">J. Miyasaki</name>
</author>
<author><name sortKey="Lang, A E" sort="Lang, A E" uniqKey="Lang A" first="A E" last="Lang">A E Lang</name>
</author>
<author><name sortKey="Fox, S H" sort="Fox, S H" uniqKey="Fox S" first="S H" last="Fox">S H Fox</name>
</author>
</analytic>
<series><title level="j">The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques</title>
<idno type="ISSN">0317-1671</idno>
<imprint><date when="2007" type="published">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Automobile Driving</term>
<term>Canada</term>
<term>Disorders of Excessive Somnolence (chemically induced)</term>
<term>Dopamine Agonists (adverse effects)</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Guideline Adherence (statistics & numerical data)</term>
<term>Guidelines as Topic</term>
<term>Humans</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Practice Patterns, Physicians' (statistics & numerical data)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dopamine Agonists</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agonists</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Canada</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Disorders of Excessive Somnolence</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Guideline Adherence</term>
<term>Practice Patterns, Physicians'</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Automobile Driving</term>
<term>Guidelines as Topic</term>
<term>Humans</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Current Health Canada instructions for use of the dopamine agonists (DA), pramipexole and ropinirole, state that Parkinson's disease (PD) patients should be told not to drive. The objective was to assess neurologists' actual clinical practice concerning driving advice they give to PD patients starting a DA.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18062452</PMID>
<DateCreated><Year>2007</Year>
<Month>12</Month>
<Day>07</Day>
</DateCreated>
<DateCompleted><Year>2008</Year>
<Month>01</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>11</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0317-1671</ISSN>
<JournalIssue CitedMedium="Print"><Volume>34</Volume>
<Issue>4</Issue>
<PubDate><Year>2007</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques</Title>
<ISOAbbreviation>Can J Neurol Sci</ISOAbbreviation>
</Journal>
<ArticleTitle>Clinical practice regarding dopamine-agonist use and driving in Parkinson's disease.</ArticleTitle>
<Pagination><MedlinePgn>438-42</MedlinePgn>
</Pagination>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Current Health Canada instructions for use of the dopamine agonists (DA), pramipexole and ropinirole, state that Parkinson's disease (PD) patients should be told not to drive. The objective was to assess neurologists' actual clinical practice concerning driving advice they give to PD patients starting a DA.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">An online survey was created consisting of 4 items regarding demographics, 5 regarding PD and driving, and 9 regarding DA use and driving. The survey was distributed to 563 neurologists.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">In total 96 neurologists (17.9%) responded. 4.4% tell patients with PD not to drive, solely because they are taking a DA. Respondents assess the patient's tendency for excessive daytime sleepiness and sleep attacks after starting a DA more frequently than after starting other dopaminergic drugs (p < 0.001).</AbstractText>
<AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">A minor proportion of the clinicians responding to our survey advise PD patients not to drive, solely because they use a DA. Such being the case, we propose that current Health Canada guidelines need revision.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Bie</LastName>
<ForeName>R M A</ForeName>
<Initials>RM</Initials>
<AffiliationInfo><Affiliation>Movement Disorders Centre, Division of Neurology University of Toronto, Toronto, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Miyasaki</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lang</LastName>
<ForeName>A E</ForeName>
<Initials>AE</Initials>
</Author>
<Author ValidYN="Y"><LastName>Fox</LastName>
<ForeName>S H</ForeName>
<Initials>SH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Can J Neurol Sci</MedlineTA>
<NlmUniqueID>0415227</NlmUniqueID>
<ISSNLinking>0317-1671</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Can J Neurol Sci. 2007 Nov;34(4):401</RefSource>
<PMID Version="1">18062445</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D001334" MajorTopicYN="Y">Automobile Driving</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006970" MajorTopicYN="N">Disorders of Excessive Somnolence</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019983" MajorTopicYN="N">Guideline Adherence</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017408" MajorTopicYN="N">Guidelines as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010818" MajorTopicYN="N">Practice Patterns, Physicians'</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year>
<Month>12</Month>
<Day>8</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2008</Year>
<Month>1</Month>
<Day>24</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2007</Year>
<Month>12</Month>
<Day>8</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">18062452</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Canada</li>
</country>
<region><li>Ontario</li>
</region>
<settlement><li>Toronto</li>
</settlement>
<orgName><li>Université de Toronto</li>
</orgName>
</list>
<tree><noCountry><name sortKey="Fox, S H" sort="Fox, S H" uniqKey="Fox S" first="S H" last="Fox">S H Fox</name>
<name sortKey="Lang, A E" sort="Lang, A E" uniqKey="Lang A" first="A E" last="Lang">A E Lang</name>
<name sortKey="Miyasaki, J" sort="Miyasaki, J" uniqKey="Miyasaki J" first="J" last="Miyasaki">J. Miyasaki</name>
</noCountry>
<country name="Canada"><region name="Ontario"><name sortKey="De Bie, R M A" sort="De Bie, R M A" uniqKey="De Bie R" first="R M A" last="De Bie">R M A. De Bie</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000848 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000848 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:18062452
   |texte=   Clinical practice regarding dopamine-agonist use and driving in Parkinson's disease.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:18062452" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Clinical practice regarding dopamine-agonist use and driving in Parkinson's disease.

Clinical practice regarding dopamine-agonist use and driving in Parkinson's disease.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki